These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29549836)

  • 1. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
    La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
    Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
    Yang J; Chen K; Zhang G; Yang QY; Li YS; Huang SZ; Wang YL; Yang W; Jiang XJ; Yan HX; Zhu JQ; Xiang R; Luo YF; Li WM; Wei YQ; Li LL; Yang SY
    Eur J Med Chem; 2018 Jan; 143():1148-1164. PubMed ID: 29133048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
    Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.
    Alqahtani T; Kumarasamy VM; Huczyński A; Sun D
    Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
    Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
    Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
    Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
    Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
    Kumarasamy VM; Shin YJ; White J; Sun D
    BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
    Wang M; Naganna N; Sintim HO
    Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAY 43-9006 inhibition of oncogenic RET mutants.
    Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
    J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
    Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
    Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
    J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.
    Gild ML; Landa I; Ryder M; Ghossein RA; Knauf JA; Fagin JA
    Endocr Relat Cancer; 2013 Oct; 20(5):659-67. PubMed ID: 23828865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP confers resistance to vandetanib in medullary thyroid cancer.
    Wang H; Tang J; Su Z
    Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.